Advances in Cardiovascular Science: From Discovery to Translation

Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2024,held from 22nd to 25th July in Chicago, Illinois.

This event features cutting-edge research and advancements in cardiovascular science, including topics like cardiac gene and cell therapy, tissue engineering, and cardiac metabolism.

Attendees will include basic cardiovascular scientists, molecular and cellular biologists, translational investigators, clinical trialists, and practicing cardiologists.

To connect with Dr. Taubel during the event, please reach out to arrange a meeting.

To find out more, click here.

Latest news

Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

First patient enrolled in telehealth study, the Pathway Study

February 25, 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event